MedTrace Logo

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

NCT03569280 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2023-07-18

No results posted yet for this study

Summary

This is a Phase 1, open-label, multicenter study of KPG-121 administered orally once daily (QD) in 28-day treatment cycles to adult subjects.

Conditions

  • Castration-Resistant Prostate Cancer

Interventions

COMBINATION_PRODUCT

Enzalutamide or Abiraterone or Apalutamid

Antitumor treatment

Sponsors & Collaborators

  • Kangpu Biopharmaceuticals, Ltd.

    lead INDUSTRY

Principal Investigators

  • Yao Wang · Kangpu Biopharmaceuticals, Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-26
Primary Completion
2023-01-10
Completion
2023-06-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03569280 on ClinicalTrials.gov